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Sir, Many thanks for letting us respond to the interesting letter
concerning our recent paper. We are grateful for the chance to
clarify the points raised, which suggest our conclusions were
too optimistic. In our paper (Kloppel et al., 2008), we used MRI
scans from pathologically proven cases of Alzheimer’s disease and
frontotemporal lobar degeneration (FTLD) to validate trained sets
for a machine learning-based support vector machine (SVM)
approach to the categorization of structural scans from normal
and each other.
This rigorous approach substantially limited the number of
available subjects, which we made perfectly clear in our article,
but which was unavoidable given our novel approach. Frost and
colleagues are right to point out that such low numbers result
in larger conﬁdence intervals than if we were able to include
more scans. This is an object of our further empirical studies—
what is the improvement in classiﬁcation gained using this tech-
nique with greater numbers of scans in the trained set? The
graph below (Fig. 1) illustrates diagnostic accuracy when the
whole brain grey matter segment is used to separate probable
Alzheimer’s disease patients from all clinical stages (MMSE range
of 3 to 30; deﬁned clinically in the same way as group III, in our
original paper) from controls. Classiﬁcation is performed repeat-
edly and after removing one Alzheimer’s disease patient and one
Figure 1 Alzheimer’s disease patients from all clinical stages
(including all subjects from group III) and an equal number of
age and sex matched cognitively normal controls are separated
repeatedly. Before each classiﬁcation, one patient and one
control are removed to illustrate the robustness of classiﬁcation
with shrinking group size.
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more variable until a steep decline occurs when less than around
20 subjects per group are included. Sufﬁce it to say we were
surprised how well Alzheimer’s disease was distinguished from
FTLD given the even smaller numbers of validated scans we had
available for that classiﬁcation. To clarify these issues, we provide
a table that supplements our data with CIs. Further, we found
very similar results using two completely independent datasets
and the CIs become relatively small when data from the ﬁrst
two datasets are combined. So, although we agree with the ques-
tion posed theoretically, practically the results stand as proof of
principle.
We also agree that some statements found on the BBC’s web-
site (BBC, 2008) are misleading. Speciﬁcally, we show that SVMs
provide a much faster classiﬁcation than full clinical workup.
Where the website misleads is in implying that they detect early
degeneration faster, which is clearly beyond the scope of the
current article and again a subject of ongoing study.
It is important to emphasize that such multivariate methods
generalize to new data. Figure 1 in our original paper illustrates
that during training, samples from those individual subjects (i.e.
normalized grey matter segments from either the whole brain
or the hippocampus area), which best separate the two groups
deﬁne the decision boundary. The ﬁgure is an example with two
dimensions but in reality, the number of dimensions equals the
number of voxels used. If a classiﬁer generalizes well, a new scan
will be assigned to the same side of the decision boundary as the
rest of a diagnostic group. It is a critical part of our results that
Table 1 Demographic information on groups I, II and IV with post-mortem conﬁrmation of Alzheimer’s disease obtained
at different centres
Group (n) Group I Group II Group III Group IV
Alzheimer’s
disease (20)
Controls
(20)
Alzheimer’s
disease (14)
Controls
(14)
Alzheimer’s
disease (33)
Controls
(57)
Alzheimer’s
disease (18)
FTLD
(19)
Sex (F/M) 11/9 10/10 5/9 5/9 10/23 16/41 6/12 8/11
Age (mean, range)
at MRI-scan
81.0 (51–102) 79.5 (55–91) 65.0 (53–85) 63.0 (51–81) 73.1 (61–80) 71.9 (61–80) 66.0
 (53–85) 61.7
 (46–73)
MMSE-score
(mean, range)
16.7 (7–29) 29.0 (27–30) 16.1
 (10–20) 29.2 (28–30) 23.5 (20–28) 29.1 (27–30) 16.2
 (5–29) 18.0 (0–26)
Years from MRI-scan
to death
(mean, range)
1.7 (0.2–3.4) NA 3.6 (0.3–7.2) NA NA NA 3.5 (0.3–7.2) 5.8 (1.3–11.0)
MMSE scores obtained around the time of scanning only available from 12 subjects;
groups are age matched (P=0.1). The ﬁrst and third image sets are from
a largely community-based sample, whereas subjects from sample II tended to be younger. No strong family history was present in any of the subjects.
FTLD=frontotemporal lobar degeneration; MMSE=Folstein Mini Mental State Examination.
(Source: Kloppel et al., 2008).
Table 2 Results of SVM classiﬁcation using grey matter from the whole brain for image analysis
Group Correct (%) (95% CI) Sensitivity (%)
a (95% CI) Speciﬁcity (%)
a (95% CI)
Alzheimer’s disease and controls group I 95.0 (81.8–99.1) 95.0 (73.1–99.7) 95.0 (73.1–99.7)
Alzheimer’s disease and controls group II 92.9 (75.1–98.8) 100 (73.2–100) 85.7 (56.2–97.5)
Alzheimer’s disease and controls group III 81.1 (71.2–88.3) 60.6 (42.2–76.6) 93.0 (82.2–97.7)
Dataset I for training, set II for testing 96.4 (79.8–99.8) 100 (73.2–100) 92.9 (64.2–99.6)
Dataset II for training, set I for testing 87.5 (72.4–95.3) 95.0 (73.1–99.7) 80.0 (55.7–93.3)
Group I+II 95.6 (86.8–98.9) 97.1 (82.9–99.8) 94.1 (78.9–99.0)
Alzheimer’s disease from Dataset II and FTLD group IV 89.2 (73.6–96.5) 83.3 (57.7–95.6) 94.7 (71.9–99.7)
aConsidering a correctly identiﬁed Alzheimer’s disease case as a true positive.
95% CIs are calculated according to the efﬁcient-score method (Newcombe, 1998; http://faculty.vassar.edu/lowry/clin1.html).
Table 3 Results of SVM classiﬁcation using only grey matter of antero-medial temporal lobe structures for analysis
Group Correct (%) (95% CI) Sensitivity (%)
a (95% CI) Speciﬁcity (%)
a (95% CI)
Alzheimer’s disease and controls group I 90.0 (81.8–99.1) 85.0 (61.1–96.0) 95.0 (73.1–99.7)
Alzheimer’s disease and controls group II 92.9 (75.1–98.8) 92.9 (64.2–99.6) 92.9 (64.2–99.6)
Alzheimer’s disease and controls group III 85.6 (76.2–91.8) 75.8 (57.4–88.3) 91.2 (80.0–96.7)
Dataset I for training, set II for testing 71.4 (51.1–86.1) 50 (24.0–76.9) 92.9 (64.2–99.6)
Dataset II for training, set I for testing 70.0 (53.3–82.9) 95.0 (73.1–99.7) 45.0 (23.8–68.0)
Group I+II 94.1 (80.5–99.1) 97.1 (82.9–99.8) 91.2 (75.2–97.7)
aConsidering a correctly identiﬁed Alzheimer’s disease case as a true positive.
95% CIs computed as above.
e102 | Brain 2009: 132; 1–3 Letter to the Editorthe decision boundary deﬁned by data from one imaging centre
using different hardware and sequences is sufﬁciently general
to separate data accurately from other imaging centres. This ability
is of great practical relevance as a library of well-deﬁned cases
can be made available to referral centres as a general trained
set to diagnose scans collected there. While our results are promis-
ing, as we pointed out in our article, ‘a formal comparison with
modern conventional clinical assessment is required’. It should
be kept in mind that we used very strict inclusion criteria and
the extension to relatively poorly deﬁned data from primary
referral centres needs to be addressed in a separate study. It is
likely that libraries from very early stages of the disease need to
be produced, which are then validated longitudinally or patho-
logically. The issue now is to optimize the variables to maximize
sensitivity and accuracy. One lesson we learned is that proper
validation of scans included in the trained set is likely to be critical.
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